Israel Englander’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$110M Sell
581,913
-720,732
-55% -$136M 0.04% 468
2026
Q1
$257M Buy
1,302,645
+104,173
+9% +$20.1M 0.11% 162
2025
Q4
$220M Buy
1,198,472
+84,799
+8% +$14.9M 0.09% 175
2025
Q3
$171M Buy
1,113,673
+541,445
+95% +$81.9M 0.07% 230
2025
Q2
$80M Buy
572,228
+96,610
+20% +$13.5M 0.04% 529
2025
Q1
$69.9M Sell
475,618
-973,345
-67% -$141M 0.04% 556
2024
Q4
$190M Buy
1,448,963
+1,389,725
+2,346% +$195M 0.09% 176
2024
Q3
$9.23M Buy
59,238
+42,914
+263% +$6.93M ﹤0.01% 2245
2024
Q2
$2.55M Sell
16,324
-1,430,231
-99% -$215M ﹤0.01% 3318
2024
Q1
$196M Buy
1,446,555
+1,140,021
+372% +$151M 0.08% 211
2023
Q4
$41.3M Buy
306,534
+287,333
+1,496% +$37.4M 0.02% 934
2023
Q3
$2.6M Sell
19,201
-184,502
-91% -$25.2M ﹤0.01% 3312
2023
Q2
$29.2M Buy
203,703
+202,175
+13,231% +$29.7M 0.01% 1093
2023
Q1
$212K Sell
1,528
-314,003
-100% -$42.2M ﹤0.01% 5134
2022
Q4
$42.8M Sell
315,531
-399,900
-56% -$50.2M 0.02% 853
2022
Q3
$78.5M Buy
715,431
+135,545
+23% +$17.2M 0.05% 455
2022
Q2
$76.6M Buy
579,886
+403,983
+230% +$53M 0.05% 417
2022
Q1
$23.3M Sell
175,903
-190,054
-52% -$22.8M 0.01% 1231
2021
Q4
$42.6M Buy
365,957
+106,471
+41% +$12.5M 0.02% 823
2021
Q3
$31.2M Buy
259,486
+239,789
+1,217% +$27.9M 0.02% 952
2021
Q2
$2.36M Sell
19,697
-43,999
-69% -$4.83M ﹤0.01% 3762
2021
Q1
$6.33M Buy
63,696
+54,085
+563% +$5.44M ﹤0.01% 2328
2020
Q4
$961K Sell
9,611
-92,475
-91% -$9.79M ﹤0.01% 3768
2020
Q3
$11.2K Sell
102,086
-30,960
-23% -$3.44M 0.01% 1159
2020
Q2
$14.1M Buy
+133,046
New +$13.7M 0.02% 971
2020
Q1
Sell
-183,548
Closed -$18.3M 3831
2019
Q4
$18.3M Buy
183,548
+176,244
+2,413% +$16.6M 0.02% 909
2019
Q3
$651K Sell
7,304
-299,435
-98% -$26M ﹤0.01% 3094
2019
Q2
$25.3M Sell
306,739
-348,760
-53% -$27.3M 0.04% 652
2019
Q1
$53M Buy
655,499
+649,858
+11,520% +$51.2M 0.08% 322
2018
Q4
$428K Sell
5,641
-393,633
-99% -$30.7M ﹤0.01% 3051
2018
Q3
$31.6M Sell
399,274
-22,688
-5% -$1.72M 0.04% 613
2018
Q2
$29.6M Sell
421,962
-654,419
-61% -$47.1M 0.04% 656
2018
Q1
$75.3M Buy
1,076,381
+375,805
+54% +$26M 0.1% 273
2017
Q4
$48.6M Sell
700,576
-212,791
-23% -$14.3M 0.07% 429
2017
Q3
$61.9M Buy
913,367
+909,229
+21,973% +$57.4M 0.09% 278
2017
Q2
$282K Buy
+4,138
New +$270K ﹤0.01% 3066
2016
Q4
Sell
-846,543
Closed -$48.1M 3320
2016
Q3
$55.6M Buy
846,543
+537,473
+174% +$35.1M 0.09% 224
2016
Q2
$18.7M Sell
309,070
-207,641
-40% -$12.1M 0.04% 569
2016
Q1
$29.1M Buy
516,711
+142,678
+38% +$8.57M 0.07% 333
2015
Q4
$25.4M Buy
374,033
+65,475
+21% +$4.29M 0.05% 485
2015
Q3
$19.6M Sell
308,558
-68,663
-18% -$4.52M 0.04% 576
2015
Q2
$24M Buy
377,221
+20,512
+6% +$1.4M 0.05% 535
2015
Q1
$24.4M Sell
356,709
-722,335
-67% -$50.2M 0.05% 567
2014
Q4
$75.9M Buy
1,079,044
+904,479
+518% +$64.8M 0.16% 122
2014
Q3
$12.5M Sell
174,565
-118,674
-40% -$8.69M 0.03% 746
2014
Q2
$21.8M Sell
293,239
-100,042
-25% -$7.23M 0.06% 438
2014
Q1
$25.5M Buy
393,281
+347,681
+762% +$22.5M 0.07% 352
2013
Q4
$2.71M Sell
45,600
-118,599
-72% -$6.44M 0.01% 1599
2013
Q3
$8.53M Sell
164,199
-131,245
-44% -$6.59M 0.03% 779
2013
Q2
$14M Buy
+295,444
New +$15M 0.04% 463

Other funds holding AZN

Israel Englander's AZN Position: Q2 2026 in Review

Israel Englander reduced its AstraZeneca (AZN) stake by 55% in Q2 2026, selling an estimated $136M and leaving 581,913 shares worth $110M. The position accounts for 0.04% of the portfolio, ranked #468.

Israel Englander first reported a position in AZN in Q2 2013 and has held it in 50 quarters since. The position peaked at $257M in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Israel Englander held 581,913 shares of AstraZeneca worth $110M as of Q2 2026.
  • Israel Englander sold 720,732 AstraZeneca shares in Q2 2026, an estimated $136M.
  • AstraZeneca made up 0.04% of Israel Englander's portfolio in Q2 2026, its #468 holding.
  • Israel Englander first reported a position in AstraZeneca in Q2 2013 and has held it in 50 quarters since.
  • Israel Englander's AstraZeneca position peaked at $257M in Q1 2026.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.